Home › Urothelial (Transitional Cell) Carcinoma › Virginia
Urothelial (Transitional Cell) Carcinoma clinical trials in Virginia
21 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in Virginia.
Cities in Virginia
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06524544Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Virginia Oncology Associates, Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07566156Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Blacksburg
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Low Moor
- and 4 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- USO - Virginia Oncology Associates, Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06774131A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07287995Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Norfolk
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07129993A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #66, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06270706A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Inova Schar Cancer Institute, Fairfax
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Falls Church
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07169734Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- The University of Virgina, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07484022A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- NEXT Oncology, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 24, 2025 · NCT06332755SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.